Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An investigator sponsored phase II trial asessing Tagraxofusp in patients with Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Next Previous
Search
Trial Profile

An investigator sponsored phase II trial asessing Tagraxofusp in patients with Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tagraxofusp (Primary)
  • Indications Blastic plasmacytoid dendritic cell neoplasm
  • Focus Therapeutic Use

Most Recent Events

  • 13 Jan 2020 According to a Stemline Therapeutics media release, the company expects to treat the first patients in the trial in 1Q 2020.
  • 07 Nov 2019 According to a Stemline Therapeutics media release, updates from this study are expected by the end of 2020, and possibly before.
  • 06 Aug 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top